Maria Wood, PA
Medical · Chattanooga, TNNPI 1366417776
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,220 of the $129,653 with a category attached, or 60.3%. Incyte Corporation accounts for 97.7% of it on its own, with 29 other manufacturers making up the rest. Among medical clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $388.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$127K
- AbbVie$997
- AstraZeneca$300
- Novartis$193
- Daiichi Sankyo Inc.$161
- Gilead$133
- plus $1K from 24 others
What the payments were for
- Consulting fees$9,7938%
- Speaking & faculty fees$78,22060%
- Travel & lodging$35,82228%
- Food & beverage$5,5084%
- Education$3110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 273 | $126,698 |
| AbbVie | 6 | $997 |
| AstraZeneca(2 entities) | 6 | $300 |
| Novartis | 9 | $193 |
| Daiichi Sankyo Inc. | 3 | $161 |
| Gilead(2 entities) | 2 | $133 |
| Novocure Inc. | 1 | $129 |
| Sanofi-aventis U.S. LLC | 1 | $96 |
| E.r. Squibb & Sons, L.L.C. | 2 | $95 |
| AVEO Pharmaceuticals, Inc. | 2 | $87 |
| Amgen | 1 | $82 |
| Johnson & Johnson(2 entities) | 4 | $75 |
| Stemline Therapeutics Inc. | 1 | $67 |
| Eisai Inc. | 2 | $60 |
| Merck | 2 | $56 |
| Taiho Oncology, Inc. | 2 | $51 |
| Beone Medicines USA, Inc. | 2 | $49 |
| Bristol Myers Squibb | 2 | $39 |
| Pfizer | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $31 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Array Biopharma Inc | 1 | $21 |
| GSK | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$121,945
- IMBRUVICA$875
- OPTUNE LUA (NOVOTTF-200T)$129
- CALQUENCE$125
- Enhertu$106
How this compares
$129,653 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $10,077 |
| XareltoRivaroxaban | 13 | $8,635 |
| Exemestane | 23 | $3,507 |
| Oxycodone Hcl | 87 | $3,048 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 116 | $2,737 |
| Ondansetron OdtOndansetron | 82 | $2,007 |
| Morphine Sulfate ErMorphine Sulfate | 31 | $1,280 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 33 | $1,000 |
| Gabapentin | 90 | $822 |
| Anastrozole | 40 | $630 |
| Dexamethasone | 51 | $626 |
| Levothyroxine Sodium | 99 | $556 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $551 |
| ValacyclovirValacyclovir Hcl | 13 | $502 |
| Temazepam | 11 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $10,07713 claims |
| Johnson & JohnsonXarelto | $75 | $8,63513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.
Other medical in Chattanooga
- Meredith McDanielChattanooga$17K
- Ginger MullinsChattanooga$9K
- Paul BatesChattanooga$8K
- Tiffany HayesChattanooga$5K
- Kirsten AndrewsChattanooga$5K
- Kaylee ChristensenChattanooga$5K
- Leona GulleyChattanooga$5K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.